Novartis

• Pharmaceuticals & Biotechnology

As a leading innovative medicines company, Novartis focuses on significant unmet medical needs, with deep expertise in core therapeutic areas including cardiovascular, renal and metabolic; oncology; immunology; and neuroscience. Leveraging key technology platforms such as chemistry, biologics, radioligand therapy, xRNA, and gene and cell therapy, we are accelerating the delivery of breakthrough innovations in China. From R&D, manufacturing and commercial operations, Novartis has established an integrated presence in China. Today, we have more than 100 clinical projects underway, and since 2022, the new drug and indication development in China has been fully synchronized with global development.

Innovation only matters if it reaches the people who need it. Since 1987, Novartis has achieved more than 120 approvals for innovative medicines and new indications in China. In 2025 alone, our medicines reached nearly 86 million Chinese patients. We actively work with partners across secto

Przejdź do strony internetowej